Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Dose-Escalation Study of AMG 386 in Japanese Adults With Advanced Solid Tumors
jRCT2080221126Phase 1
- Sponsor
- Takeda
- Start
- Jun 2010
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of trebananib in Nonhematologic neoplasms, sponsored by Takeda. Primary endpoints: Safety and tolerability of AMG 386 and Pharmacokinetics of AMG 386.
02
Drugs
trebananib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2080221126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221126.